Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Xention

Xention
2002 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
2ndary - Private LATEST DEAL TYPE
11 INVESTORS
Description

Developer of novel therapies created for the treatment of atrial fibrillation. The company is developing drug candidates that modulate two novel, but well characterised, ion channels and expects to develop breakthrough products in this area of huge unmet medical need. It's ion channel-modulating drugs are used for the treatment of atrial fibrillation, overactive bladder, pain and autoimmune diseases.

Website
Formerly Known As
Xention Discovery
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Biotechnology
Primary Office
  • 38 High Street
  • Newmarket
  • Suffolk CB8 8LB
  • England, United Kingdom

+44 01223 000000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Xention’s full profile, request a free trial.

Xention Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Secondary Transaction - Private 000.00 Completed Generating Revenue
7. Later Stage VC 00.000 000.00 Completed Generating Revenue
6. Later Stage VC (Series D) 23-Nov-2010 000.00 000.00 Completed Generating Revenue
5. Early Stage VC 25-Jun-2010 000.00 Completed Generating Revenue
4. Later Stage VC 31-Mar-2008 000.00 Completed Generating Revenue
3. Early Stage VC 18-Jul-2005 000.00 000.00 Completed Startup
2. Early Stage VC 16-Sep-2003 $6.34M $12.8M Completed Startup
1. Early Stage VC 01-Aug-2002 $6.5M $6.5M Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Xention Competitors (25)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Enterprise Therapeutics Venture Capital-Backed Brighton, United Kingdom 0 000.00 00000000000 000.00
00000 000000000 Formerly VC-backed South San Francisco, CA 00 0000 000000&0 0000
0000000000 Formerly VC-backed Cambridge, MA 00 0000 000000&0 0000
000000000 00000000 Formerly VC-backed San Diego, CA 00 0000 000000&0 0000
000 000000000 Corporation Gainesville, FL 0 00.000 000000000000 00.000
To view this company’s complete list of competitors, request access »

Xention Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Seroba Life Sciences Venture Capital Minority 000 0000 000000 0
Foresight Group PE/Buyout Minority 000 0000 000000 0
Gresham House Strategic Public Equity PE/Buyout Minority 000 0000 000000 0
ABN AMRO AAH.AS Investment Bank Minority 000 0000 000000 0
Omnes Capital PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Xention Executive Team (5)

Name Title Board
Seat
Contact
Info
Timothy Brears Ph.D Chief Executive Officer & Board Member
Keith McCullagh Ph.D Board Member & Executive Chairman

3 Former Executives

You’re viewing 2 of 5 executives. Get the full list »

Xention Board Members (13)

Name Representing Role Since Contact
Info
Alan O'Connell Ph.D Seroba Life Sciences Board Member 000 0000
Graham Fagg Ph.D Self Board Member 000 0000
Jonathan Gee Ph.D Gresham House Strategic Public Equity Board Member 000 0000
Keith McCullagh Ph.D Xention Board Member & Executive Chairman 000 0000
Kenneth Cunningham Self Board Member 000 0000

6 Former Board Members

You’re viewing 5 of 13 board members. Get the full list »